What if artificial intelligence could help us unlock the mysteries of the brain—and speed up the search for new treatments for mental illness and age-related brain diseases?
Join us for a fascinating, accessible conversation with AI research experts Dr. Shizhong Han and Dr. Michael Nagle of the Lieber Institute for Brain Development. These pioneering scientists are using cutting-edge AI to accelerate discoveries in mental health and aging—revealing hidden patterns in the brain, designing new drug candidates, and changing what’s possible in brain science.
In this live webinar, you’ll learn:
Whether you’re personally impacted by mental illness, caring for someone facing cognitive decline, or simply curious about the future of brain health—this is a rare opportunity to hear directly from the scientists leading the charge.
Shizhong Han is a Lead Investigator at the Lieber Institute and an Associate Professor of Psychiatry and Behavioral Sciences at The Johns Hopkins School of Medicine. His research aims to understand the genetic basis of brain disorders and translate genetic discoveries to novel therapeutics. To achieve these goals, research in his group employs advanced statistical genetic methods, bioinformatics tools and deep learning techniques that integrates multi-omics datasets. Some of ongoing projects include: 1) understanding the roles of noncoding genetic variations in gene regulation and brain disorders, 2) identifying core genes and gene regulatory circuits involved in brain disorders, 3) developing novel therapeutics based on drug-induced gene expression perturbation signatures.
Michael’s research interests center on the development and application of machine learning and high-performance computing methods to analyze biological datasets, which a special interest in highly polygenic traits controlled by many -omic variables. His PhD and postdoctoral work involved the study of regeneration in the model tree Populus, and relied on the development of methods for computer vision and genetic association mapping. With the Lieber Institute, Michael is now applying his background to advancing knowledge and developing treatments for schizophrenia, a condition with incredible polygenic complexity.